Univariate analysis: LS BMD results
| . | All patients . | Chemotherapy group . | HSCT group . | |||
|---|---|---|---|---|---|---|
| Mean Z-score ± SEM . | Univariable P . | Mean Z-score ± SEM . | Univariable P . | Mean Z-score ± SEM . | Univariable P . | |
| Patient and disease characteristics | ||||||
| Sex | ||||||
| Female | −0.35 ± 0.11 | .89 | −0.28 ± 0.13 | .26 | −0.55 ± 0.19 | .16 |
| Male | −0.38 ± 0.13 | −0.51 ± 0.17 | −0.17 ± 0.18 | |||
| Initial diagnosis | ||||||
| ALL | −0.32 ± 0.09 | .27 | −0.36 ± 0.11 | .47 | −0.20 ± 0.16 | .24 |
| AML | −0.56 ± 0.22 | −0.65 ± 0.52 | −0.53 ± 0.24 | |||
| Age at diagnosis | NA | .72 | NA | .34 | NA | .07 |
| Age at HSCT | NA | .02 | ||||
| Follow-up | NA | .93 | NA | .57 | NA | .49 |
| Treatment modalities | ||||||
| Corticotherapy | ||||||
| No | −0.71 ± 0.24 | .10 | −0.65 ± 0.52 | .47 | −0.75 ± 0.24 | .07 |
| Yes | −0.31 ± 0.09 | −0.36 ± 0.11 | −0.19 ± 0.15 | |||
| Dexamethasone | ||||||
| No | −0.44 ± 0.15 | .45 | −0.39 ± 0.23 | .97 | −0.50 ± 0.19 | .16 |
| Yes | −0.31 ± 0.10 | −0.38 ± 0.11 | −0.12 ± 0.18 | |||
| HSCT | ||||||
| No | −0.39 ± 0.11 | .74 | ||||
| Yes | −0.33 ± 0.13 | |||||
| TBI | ||||||
| No | −0.40 ± 0.24 | .23 | ||||
| Yes | −0.22 ± 0.16 | |||||
| Type of graft | ||||||
| Allograft | −0.36 ± 0.18 | .71 | ||||
| Autograft | −0.26 ± 0.20 | |||||
| Posttransplantation steroid therapy | ||||||
| No | −0.55 ± 0.14 | .69 | ||||
| Yes | −0.41 ± 0.32 | |||||
| Transplantation-related complications | ||||||
| Significant GVHD* | ||||||
| No | −0.26 ± 0.17 | .48 | ||||
| Yes | −0.47 ± 0.20 | |||||
| Hypogonadism | ||||||
| No | −0.16 ± 0.19 | |||||
| Compensated | −0.38 ± 0.25 | .37 | ||||
| Uncompensated | −0.65 ± 0.27 | |||||
| GHD | ||||||
| No | −0.32 ± 0.14 | .88 | ||||
| Yes | −0.40 ± 0.32 | |||||
| . | All patients . | Chemotherapy group . | HSCT group . | |||
|---|---|---|---|---|---|---|
| Mean Z-score ± SEM . | Univariable P . | Mean Z-score ± SEM . | Univariable P . | Mean Z-score ± SEM . | Univariable P . | |
| Patient and disease characteristics | ||||||
| Sex | ||||||
| Female | −0.35 ± 0.11 | .89 | −0.28 ± 0.13 | .26 | −0.55 ± 0.19 | .16 |
| Male | −0.38 ± 0.13 | −0.51 ± 0.17 | −0.17 ± 0.18 | |||
| Initial diagnosis | ||||||
| ALL | −0.32 ± 0.09 | .27 | −0.36 ± 0.11 | .47 | −0.20 ± 0.16 | .24 |
| AML | −0.56 ± 0.22 | −0.65 ± 0.52 | −0.53 ± 0.24 | |||
| Age at diagnosis | NA | .72 | NA | .34 | NA | .07 |
| Age at HSCT | NA | .02 | ||||
| Follow-up | NA | .93 | NA | .57 | NA | .49 |
| Treatment modalities | ||||||
| Corticotherapy | ||||||
| No | −0.71 ± 0.24 | .10 | −0.65 ± 0.52 | .47 | −0.75 ± 0.24 | .07 |
| Yes | −0.31 ± 0.09 | −0.36 ± 0.11 | −0.19 ± 0.15 | |||
| Dexamethasone | ||||||
| No | −0.44 ± 0.15 | .45 | −0.39 ± 0.23 | .97 | −0.50 ± 0.19 | .16 |
| Yes | −0.31 ± 0.10 | −0.38 ± 0.11 | −0.12 ± 0.18 | |||
| HSCT | ||||||
| No | −0.39 ± 0.11 | .74 | ||||
| Yes | −0.33 ± 0.13 | |||||
| TBI | ||||||
| No | −0.40 ± 0.24 | .23 | ||||
| Yes | −0.22 ± 0.16 | |||||
| Type of graft | ||||||
| Allograft | −0.36 ± 0.18 | .71 | ||||
| Autograft | −0.26 ± 0.20 | |||||
| Posttransplantation steroid therapy | ||||||
| No | −0.55 ± 0.14 | .69 | ||||
| Yes | −0.41 ± 0.32 | |||||
| Transplantation-related complications | ||||||
| Significant GVHD* | ||||||
| No | −0.26 ± 0.17 | .48 | ||||
| Yes | −0.47 ± 0.20 | |||||
| Hypogonadism | ||||||
| No | −0.16 ± 0.19 | |||||
| Compensated | −0.38 ± 0.25 | .37 | ||||
| Uncompensated | −0.65 ± 0.27 | |||||
| GHD | ||||||
| No | −0.32 ± 0.14 | .88 | ||||
| Yes | −0.40 ± 0.32 | |||||
Significant GVHD indicates acute GVHD grades II, III, or IV or chronic extensive GVHD.